Search research articles
Contact Us
Filters
Showing results (31-40 of 39) with videos related to
Page
of 4
Sort By:
You have reached the last page of results.
This site can display upto 39 results.
Blood Neoplasia
|
January 15, 2026
Tisagenlecleucel in combination with ibrutinib in adults with relapsed and/or refractory large B-cell lymphomas
Julio C Chavez, Ellen Napier, Attilio Bondanza, et al.
Cancer Research
|
January 28, 2004
Selective growth inhibition of tumor cells by a novel histone deacetylase inhibitor, NVP-LAQ824
Peter Atadja, Lin Gao, Paul Kwon, et al.
Nature
|
January 17, 2020
Design and synthesis of multigrain nanocrystals via geometric misfit strain
Myoung Hwan Oh, Min Gee Cho, Dong Young Chung, et al.
The Lancet. Gastroenterology & Hepatology
|
December 5, 2024
Efficacy and safety of filgotinib as induction and maintenance therapy for Crohn's disease (DIVERSITY): a phase 3, double-blind, randomised, placebo-controlled trial
Séverine Vermeire, Stefan Schreiber, David T Rubin, et al.
Biorxiv : the Preprint Server for Biology
|
November 24, 2025
De novo design of metal-oxide templating proteins
Amijai Saragovi, Harley Pyles, Timothy F Huddy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 17, 2018
Preclinical Antitumor Activity of a Novel Anti-c-KIT Antibody-Drug Conjugate against Mutant and Wild-type c-KIT-Positive Solid Tumors
Tinya Abrams, Anu Connor, Christie Fanton, et al.
Journal of Medicinal Chemistry
|
October 3, 2003
N-hydroxy-3-phenyl-2-propenamides as novel inhibitors of human histone deacetylase with in vivo antitumor activity: discovery of (2E)-N-hydroxy-3-[4-[[(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2-propenamide (NVP-LAQ824)
Stacy W Remiszewski, Lidia C Sambucetti, Kenneth W Bair, et al.
Molecular Cancer Therapeutics
|
April 21, 2021
PCA062, a P-cadherin Targeting Antibody-Drug Conjugate, Displays Potent Antitumor Activity Against P-cadherin-expressing Malignancies
Qing Sheng, Joseph A D'Alessio, Daniel L Menezes, et al.
Journal of Medicinal Chemistry
|
June 10, 2011
Optimization of the in vitro cardiac safety of hydroxamate-based histone deacetylase inhibitors
Michael D Shultz, Xueying Cao, Christine H Chen, et al.
Page
of 4
Search research articles
Search
Showing results (31-40 of 39) with videos related to
Sort By:
Page
of 4
You have reached the last page of results.
This site can display upto 39 results.
Blood Neoplasia
|
January 15, 2026
Tisagenlecleucel in combination with ibrutinib in adults with relapsed and/or refractory large B-cell lymphomas
Julio C Chavez, Ellen Napier, Attilio Bondanza, et al.
Cancer Research
|
January 28, 2004
Selective growth inhibition of tumor cells by a novel histone deacetylase inhibitor, NVP-LAQ824
Peter Atadja, Lin Gao, Paul Kwon, et al.
Nature
|
January 17, 2020
Design and synthesis of multigrain nanocrystals via geometric misfit strain
Myoung Hwan Oh, Min Gee Cho, Dong Young Chung, et al.
The Lancet. Gastroenterology & Hepatology
|
December 5, 2024
Efficacy and safety of filgotinib as induction and maintenance therapy for Crohn's disease (DIVERSITY): a phase 3, double-blind, randomised, placebo-controlled trial
Séverine Vermeire, Stefan Schreiber, David T Rubin, et al.
Biorxiv : the Preprint Server for Biology
|
November 24, 2025
De novo design of metal-oxide templating proteins
Amijai Saragovi, Harley Pyles, Timothy F Huddy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 17, 2018
Preclinical Antitumor Activity of a Novel Anti-c-KIT Antibody-Drug Conjugate against Mutant and Wild-type c-KIT-Positive Solid Tumors
Tinya Abrams, Anu Connor, Christie Fanton, et al.
Journal of Medicinal Chemistry
|
October 3, 2003
N-hydroxy-3-phenyl-2-propenamides as novel inhibitors of human histone deacetylase with in vivo antitumor activity: discovery of (2E)-N-hydroxy-3-[4-[[(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2-propenamide (NVP-LAQ824)
Stacy W Remiszewski, Lidia C Sambucetti, Kenneth W Bair, et al.
Molecular Cancer Therapeutics
|
April 21, 2021
PCA062, a P-cadherin Targeting Antibody-Drug Conjugate, Displays Potent Antitumor Activity Against P-cadherin-expressing Malignancies
Qing Sheng, Joseph A D'Alessio, Daniel L Menezes, et al.
Journal of Medicinal Chemistry
|
June 10, 2011
Optimization of the in vitro cardiac safety of hydroxamate-based histone deacetylase inhibitors
Michael D Shultz, Xueying Cao, Christine H Chen, et al.
Page
of 4